Eurofins Scientific (ERF) Q3 2024 earnings summary

Executive summary

• 9M 2024 revenues reached €5,142m, up 6.7% year-over-year, driven by strong organic growth in Core Business, despite FX headwinds and BioPharma pipeline reset.

• Profitability and cash flow objectives for 2024 are reaffirmed, with higher profit margins expected and continued progress on hub-and-spoke lab network and IT investments.

• Organic growth momentum remained robust in Q3 2024, with strong performance in Environment, Food, and Consumer Testing, while BioPharma and Agroscience segments were softer.

• M&A activity included 24 acquisitions in 9M 2024, contributing €77m to revenues, while lower M&A spend enabled increased share buybacks.

• Significant expansion in service offerings, including sustainability and deforestation impact assessments, and new laboratory openings.

Financial highlights

• Q3 2024 revenues were €1,723m, up 7.0% year-over-year, with Core Business organic growth at 4.4%.

• Margins in Q3 exceeded initial plans, with profitability continuing to improve and adjusted EBITDA margin for FY 2024 expected to increase.

• FX headwinds reduced revenue growth by 0.5% in 9M 2024.

• Cash flow objectives for the year are expected to be met, with FCFF before investment in owned sites €800m–€840m.

• Start-ups contributed 0.9% to organic growth in 9M 2024.

Outlook and guidance

• FY 2024 revenue expected close to €7bn, adjusted EBITDA €1.525bn–€1.575bn, and FCFF before investment in owned sites €800m–€840m.

• 2027 objectives reaffirmed: revenues approaching €10bn, margin 24%, adjusted EBITDA approaching €1.5bn, and financial leverage below 1.5x.

• Organic growth targeted at 6.5% p.a. from 2024 to 2027, with €250m average annual revenues from acquisitions.

• BioPharma recovery anticipated in H2 2025, with clinical trial activities expected to restart; Agroscience outlook remains uncertain due to client R&D spending reductions.

• No expected impact from changes in French tax rates due to company structure and activity thresholds.